Vault-13

Paradigm Biocapital Advisors LP

NEW YORK, NY · CIK 1855655 · 13F filing filed 2024-11-14

SEC-registered investment adviser since 2021 · limited partnership

As an employer

$2.9bn reported value +9.4% vs Q2 2024
31positions
68.1%in top 10
7 new 15 added 7 reduced 11 sold out vs Q2 2024

Options: 2 call positions ($98.4m notional), 0 put positions (— notional) – listed below, not included above.

Holdings, Q3 2024

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 NUVALENT INC COM COM 5,000,000 $511.5m17.90% 17.90% AddedShares held: Q4 2023 3.9m, Q1 2024 4.2m, Q2 2024 4.6m, Q3 2024 5.0m +428.3k +428,322 9.4%
2 ARCELLX INC COMMON STOCK ACLX ACLX 4,000,000 $334.0m11.69% 11.69% AddedShares held: Q4 2023 3.7m, Q1 2024 3.8m, Q2 2024 3.8m, Q3 2024 4.0m +151.9k +151,905 4.0%
3 ARGENX SE SPONSORED ADR ARGX ARGX 480,374 $260.4m9.11% 9.11% ReducedShares held: Q4 2023 422.6k, Q1 2024 552.1k, Q2 2024 538.1k, Q3 2024 480.4k -57.8k -57,765 -10.7%
4 REVOLUTION MEDICINES INC COM RVMD RVMD 5,314,089 $241.0m8.43% 8.43% AddedShares held: Q4 2023 0, Q1 2024 2.9m, Q2 2024 5.3m, Q3 2024 5.3m +55.0k +55,000 1.1%
5 CRINETICS PHARMACEUTICALS IN COM CRNX CRNX 2,516,686 $128.6m4.50% 4.50% AddedShares held: Q4 2023 2.3m, Q1 2024 3.1m, Q2 2024 2.5m, Q3 2024 2.5m +3.4k +3,384 0.1%
6 MERUS N V COM MRUS MRUS 2,454,917 $122.6m4.29% 4.29% AddedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 2.0m, Q3 2024 2.5m +435.1k +435,103 21.5%
7 JANUX THERAPEUTICS INC COM JANX JANX 2,400,574 $109.1m3.82% 3.82% AddedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 1.6m, Q3 2024 2.4m +836.1k +836,122 53.5%
8 KURA ONCOLOGY INC COM KURA KURA 4,331,321 $84.6m2.96% 2.96% ReducedShares held: Q4 2023 1.3m, Q1 2024 3.1m, Q2 2024 4.5m, Q3 2024 4.3m -208.1k -208,060 -4.6%
9 TARSUS PHARMACEUTICALS INC COM TARS TARS 2,440,445 $80.3m2.81% 2.81% AddedShares held: Q4 2023 1.0m, Q1 2024 2.9m, Q2 2024 2.4m, Q3 2024 2.4m +5.0k +5,029 0.2%
10 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 2,789,172 $74.4m2.61% 2.61% AddedShares held: Q4 2023 0, Q1 2024 2.4m, Q2 2024 2.3m, Q3 2024 2.8m +463.7k +463,723 19.9%
11 DISC MEDICINE INC COM IRON IRON 1,497,720 $73.6m2.58% 2.58% ReducedShares held: Q4 2023 2.4m, Q1 2024 2.4m, Q2 2024 2.7m, Q3 2024 1.5m -1.2m -1,206,998 -44.6%
12 VAXCYTE INC COM PCVX PCVX 627,732 $71.7m2.51% 2.51% AddedShares held: Q4 2023 0, Q1 2024 1.2m, Q2 2024 627.2k, Q3 2024 627.7k +530 +530 0.1%
13 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 2,895,689 $65.9m2.31% 2.31% ReducedShares held: Q4 2023 4.8m, Q1 2024 5.0m, Q2 2024 2.9m, Q3 2024 2.9m -660 -660 -0.0%
14 OLEMA PHARMACEUTICALS INC COM OLMA OLMA 5,503,600 $65.7m2.30% 2.30% ReducedShares held: Q4 2023 7.9m, Q1 2024 7.9m, Q2 2024 7.9m, Q3 2024 5.5m -2.4m -2,400,000 -30.4%
15 ARVINAS INC COM ARVN ARVN 2,339,961 $57.6m2.02% 2.02% ReducedShares held: Q4 2023 931.3k, Q1 2024 2.6m, Q2 2024 2.4m, Q3 2024 2.3m -98.2k -98,188 -4.0%
16 Y-MABS THERAPEUTICS INC COM YMAB YMAB 4,086,346 $53.7m1.88% 1.88% AddedShares held: Q4 2023 0, Q1 2024 2.2m, Q2 2024 3.9m, Q3 2024 4.1m +215.8k +215,752 5.6%
17 COGENT BIOSCIENCES INC COM COGT COGT 4,609,762 $49.8m1.74% 1.74% AddedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 3.6m, Q3 2024 4.6m +985.4k +985,420 27.2%
18 VERA THERAPEUTICS INC CL A VERA VERA 1,096,851 $48.5m1.70% 1.70% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 1.1m
19 MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD MLTX MLTX 931,480 $47.0m1.64% 1.64% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 931.5k
20 BEIGENE LTD SPONSORED ADR ONC ONC 200,336 $45.0m1.57% 1.57% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 200.3k
21 IMMATICS N.V SHS IMTX IMTX 3,904,862 $44.6m1.56% 1.56% AddedShares held: Q4 2023 2.1m, Q1 2024 2.8m, Q2 2024 3.4m, Q3 2024 3.9m +482.9k +482,897 14.1%
22 APOGEE THERAPEUTICS INC COM COM 701,817 $41.2m1.44% 1.44% AddedShares held: Q4 2023 0, Q1 2024 330.0k, Q2 2024 330.0k, Q3 2024 701.8k +371.8k +371,817 112.7%
23 IMMUNOVANT INC COM IMVT IMVT 1,362,827 $38.9m1.36% 1.36% UnchangedShares held: Q4 2023 0, Q1 2024 799.1k, Q2 2024 1.4m, Q3 2024 1.4m
24 CULLINAN THERAPEUTICS INC COM CGEM CGEM 2,321,013 $38.9m1.36% 1.36% AddedShares held: Q4 2023 0, Q1 2024 1.3m, Q2 2024 1.5m, Q3 2024 2.3m +778.2k +778,208 50.4%
25 SPYRE THERAPEUTICS INC COM NEW SYRE SYRE 1,267,581 $37.3m1.30% 1.30% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 1.3m
26 PLIANT THERAPEUTICS INC COM PLRX PLRX 3,104,486 $34.8m1.22% 1.22% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 3.1m
27 KEROS THERAPEUTICS INC COM KROS KROS 525,037 $30.5m1.07% 1.07% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 525.0k
28 ERASCA INC COM ERAS ERAS 10,668,141 $29.1m1.02% 1.02% AddedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 7.2m, Q3 2024 10.7m +3.4m +3,418,141 47.1%
29 ORUKA THERAPEUTICS INC COM ORKA ORKA 719,660 $17.6m0.62% 0.62% NewShares held: Q4 2023 0, Q1 2024 0, Q2 2024 0, Q3 2024 719.7k
30 PERSPECTIVE THERAPEUTICS INC COM NEW CATX CATX 919,692 $12.3m0.43% 0.43% UnchangedShares held: Q4 2023 0, Q1 2024 0, Q2 2024 919.7k, Q3 2024 919.7k
31 COMPASS PATHWAYS PLC SPONSORED ADS CMPS CMPS 1,160,000 $7.3m0.26% 0.26% ReducedShares held: Q4 2023 2.3m, Q1 2024 2.4m, Q2 2024 2.3m, Q3 2024 1.2m -1.2m -1,175,926 -50.3%

Sold out since Q2 2024

SecurityTickerShares held beforeValue then
SAREPTA THERAPEUTICS INC SRPT SRPT 947,574 $149.7m947.6k shares
CEREVEL THERAPEUTICS HLDNG I CERE CERE 2,330,508 $95.3m2.3m shares
ASCENDIS PHARMA A/S 664,307 $90.6m664.3k shares
XENON PHARMACEUTICALS INC XENE XENE 2,043,280 $79.7m2.0m shares
LEGEND BIOTECH CORP LEGN LEGN 1,203,308 $53.3m1.2m shares
BRIDGEBIO PHARMA INC BBIO BBIO 1,089,492 $27.6m1.1m shares
VERONA PHARMA PLC VRNA VRNA 721,087 $10.4m721.1k shares
ALX ONCOLOGY HLDGS INC ALXO ALXO 1,575,605 $9.5m1.6m shares
VOR BIOPHARMA INC 6,457,293 $6.5m6.5m shares
ACRIVON THERAPEUTICS INC ACRV ACRV 659,724 $3.8m659.7k shares
TSCAN THERAPEUTICS INC TCRX TCRX 353,886 $2.1m353.9k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
ARCELLX INC ACLX · Call ACLXCall 800,000 $66.8m800.0k shares New
VAXCYTE INC PCVX · Call PCVXCall 276,800 $31.6m276.8k shares New

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 OLMA 10.0%≈ $92.9m 13G 2025-02-14
EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 EWTX 9.5%≈ $415.1m +3.3 pts 13G 2026-08-14
ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 ACHV 9.2%≈ $64.7m new 13G 2026-04-24
ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 ASMB 7.8%≈ $42.7m +2.4 pts 13G 2026-08-14
VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 VRDN 6.1%≈ $123.5m +1.0 pts 13G 2026-08-14
TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 TYRA 5.8%≈ $110.9m new 13G 2026-09-17
LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 LXEO 5.3%≈ $19.4m -3.0 pts 13G 2026-08-14
MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 MBX 5.2%≈ $137.6m new 13G 2026-06-24
SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 SYRE 5.1%≈ $395.7m new 13G 2026-10-01
JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 JBIO 5.1%≈ $69.0m new 13G 2026-07-17

Trades reported as a company insider in Q3 2024

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2024-08-01 OLEMA PHARMACEUTICALS INC 10% owner · By: Paradigm BioCapital International Fund Ltd. OLMA Sold 1,870,499 $27.9m1.9m shares -28%
2024-08-01 OLEMA PHARMACEUTICALS INC 10% owner · By: One or more separately managed accounts OLMA Sold 529,501 $7.9m529.5k shares -40%